Drug Profile

MK 1167

Alternative Names: MK-1167

Latest Information Update: 17 Jul 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Merck Sharp & Dohme
Class Antidementias; Small molecules
Mechanism of Action Alpha7 nicotinic acetylcholine receptor modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Alzheimer's disease

Most Recent Events

01 Jul 2026 Merck Sharp & Dohme terminates phase II trial in Alzheimer's disease (Adjunctive treatment) in Argentina, Canada, Italy, Japan, Netherlands, South Korea, Spain and United Kingdom (PO, Capsule) (NCT06721156)
20 May 2026 Merck Sharp & Dohme completes a phase I trial for Healthy volunteers in USA (NCT07334860)
09 Apr 2026 Merck Sharp & Dohme completes a phase I pharmacokinetics trial for Healthy volunteers in USA (PO) (NCT07266818)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com